Additional file 9 of Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax

Additional file 9: Fig S6. Genotype of WT mice (182WT) and miR-182-knockout (182KO) mice and schedule for BCR-ABL (P190)-induced B-ALL mouse model. (A) Genotyping PCR for 182WT and 182KO mice. (B) Schedule for BCR-ABL (P190)-induced B-ALL mouse model. (C) Murine miR-182 expression was measured by qRT-PCR in BM GFP+ cells from 182WT B-ALL mice and 182KO B-ALL mice. (D) CD3, B220, Mac-1, and Gr-1 expressions were measured in BM GFP+ cells from primary 182WT and 182KO B-ALL mice by flow cytometry. Shown are the representative flow cytometry plots (left) and statistical analysis of T lymphocyte (CD3+), B lymphocyte (B220+), monocyte and granulocyte (Mac-1+ or Gr-1+) (Right). ***P